NASDAQ false 0001205922 0001205922 2024-02-08 2024-02-08





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 8, 2024



Vaccinex, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-38624   16-1603202

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


1895 Mount Hope Avenue, Rochester, New York   14620
(Address of principal executive offices)   (Zip Code)

(585) 271-2700

(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   VCNX   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 




Item 5.07

Submission of Matters to a Vote of Security Holders.

At the special meeting of stockholders of Vaccinex, Inc. (the “Company”) held on February 8, 2024, the Company’s stockholders voted on the matter described below.


Proposal 1.    The Company’s stockholders approved and adopted an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of its issued common stock with one of several specified ratios between one-for-four and one-for-fourteen shares (the “Reverse Stock Split”), at the discretion of the Company’s Board of Directors (the “Board”).


Votes For


Votes Against


Votes Abstained

7,075,432   258,830   37,142


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: February 13, 2024    

/s/ Scott E. Royer

      Scott E. Royer
      Chief Financial Officer
Document and Entity Information
Feb. 08, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001205922
Document Type 8-K
Document Period End Date Feb. 08, 2024
Entity Registrant Name Vaccinex, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38624
Entity Tax Identification Number 16-1603202
Entity Address, Address Line One 1895 Mount Hope Avenue
Entity Address, City or Town Rochester
Entity Address, State or Province NY
Entity Address, Postal Zip Code 14620
City Area Code (585)
Local Phone Number 271-2700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol VCNX
Entity Emerging Growth Company true
Entity Ex Transition Period false

Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vaccinex Charts.
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vaccinex Charts.